Accessibility StatementSkip Navigation FRANKLIN LAKES, N.J., Nov. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a prospective, multi-center study evaluating the Revelloâ"¢ Vascular Covered Stent in patients with peripheral arterial disease (PAD). Continue Reading BD Achieves Milestone in AGILITY Study of Revel ...